Stockhub

Bellerophon Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

5 August 2022

  • curprev 00:4000:40, 5 August 2022‎ Paris talk contribs‎ 1,097 bytes +1,097‎ Created page with "Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Bellerophon_Therapeutics,_Inc.’